Gammagard S-D bulk
Ended Awarded Last action
- Contract number
- 36C26025F0019
- Awardee
-
Takeda Pharmaceuticals America, Inc. UEI DDEVYUAXJ624 Part of Takeda Pharmaceutical Company LIMITED
- Awarding agency
-
Veterans Integrated Service Network 20
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $46,570
Award facts
- Contract value 100% obligated
- $46,570.29 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Lexington, MA 02421, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$70,397 | |
| Original award | $116,967 |
About this award
Takeda Pharmaceuticals America Inc., a subsidiary of Japan-based Takeda Pharmaceutical Company Limited, received a $46,570.29 firm fixed-price delivery order from the Department of Veterans Affairs (Veterans Integrated Service Network 20) on October 1, 2024, for GAMMAGARD S-D Bulk, an immune globulin product used to treat immunological conditions. The contract carries no set-aside designation due to the specialized and often single-source nature of this biopharmaceutical product. Performance will occur in Lexington, Massachusetts, with an ultimate completion date of September 30, 2025. This delivery order is a child contract issued under Takeda's single-award Blanket Purchase Agreement with the VA National Acquisition Center valued at $131,039,520.00, which operates through the General Services Administration Pharmaceuticals and Drugs Schedule (FSS-61-IB) contract vehicle for the period July 15, 2025, through July 14, 2026.
The BPA structure streamlines procurement for Veterans Integrated Service Networks and other authorized federal healthcare agencies by leveraging pre-negotiated terms and established pricing, enabling rapid access to advanced pharmaceutical interventions for veteran and federal beneficiary populations without requiring individual competitive procurements. Takeda's comprehensive BPA portfolio includes nine specialized pharmaceutical products addressing complex medical conditions including hereditary angioedema, hemophilia, immune disorders, rare genetic metabolic disorders, and short bowel syndrome, positioning the company as a critical supplier to federal healthcare operations through its delivery order execution across multiple therapeutic areas.
Quick answers
Who was awarded contract 36C26025F0019?
36C26025F0019 was awarded to Takeda Pharmaceuticals America, Inc. by Veterans Integrated Service Network 20 (Veterans Health Administration) on October 1, 2024.
How much is contract 36C26025F0019 worth?
The government has obligated $46,570 on 36C26025F0019.
Is contract 36C26025F0019 an order under another contract?
Yes. 36C26025F0019 is a delivery order under V797D50492, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C26025F0019 competed?
The extent of competition for 36C26025F0019 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award